Nyan Myat, Sato Daisuke, Kihara Hidemichi, Machida Tetsu, Ohya Keiichi, Kasugai Shohei
Oral Implantology and Regenerative Dental Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8549, Japan.
Clin Oral Implants Res. 2009 Mar;20(3):280-7. doi: 10.1111/j.1600-0501.2008.01639.x.
Although local application of statins stimulates bone formation, high dose of simvastatin induces inflammation.
A study was conducted to test the hypothesis that maximum bone regeneration with less inflammation would be achieved by combining an optimal dose of simvastatin with alpha-tricalcium phosphate (alpha-TCP), which is an osteoconductive biomaterial capable of releasing the drug gradually.
Bilateral 5-mm-diameter calvarial defects were created in adult Wistar rats and filled with preparations of different doses of simvastatin (0, 0.01, 0.1, 0.25 and 0.5 mg) combined with alpha-TCP particles or left empty. The animals were sacrificed at 2, 4 and 8 weeks and analyzed radiologically and histologically. Half of the animals of 4 and 8 weeks were labeled with fluorescence dyes and histomorphometrically analyzed.
Simvastatin doses of 0.25 and 0.5 mg caused inflammation of the soft tissue at the graft site whereas control and other doses did not. The micro-CT analysis revealed that the alpha-TCP with 0.1 mg simvastatin (TCP-0.1) group yielded significantly higher bone volumes than untreated control group at all three time points (249%, 227% and 266% at 2, 4 and 8 weeks, respectively). The percentage of defect closure, bone mineral content and bone mineral density were also higher in the TCP-0.1 group than in the other groups.
When combined with alpha-TCP particles, 0.1 mg simvastatin is the optimal dose for stimulation of the maximum bone regeneration in rat calvarial defects without inducing inflammation and it could be applied as an effective bone graft material.
尽管他汀类药物局部应用可刺激骨形成,但高剂量辛伐他汀会引发炎症。
进行一项研究以验证以下假设:将最佳剂量的辛伐他汀与α-磷酸三钙(α-TCP,一种能够逐渐释放药物的骨传导生物材料)联合使用,可实现最大程度的骨再生且炎症反应较小。
在成年Wistar大鼠双侧制造直径5毫米的颅骨缺损,并用不同剂量辛伐他汀(0、0.01、0.1、0.25和0.5毫克)与α-TCP颗粒的制剂填充,或保持缺损为空。在2、4和8周时处死动物,进行放射学和组织学分析。对4周和8周的动物中的一半用荧光染料标记并进行组织形态计量学分析。
0.25毫克和0.5毫克剂量的辛伐他汀导致移植部位软组织炎症,而对照组和其他剂量则未出现。显微CT分析显示,含0.1毫克辛伐他汀的α-TCP(TCP-0.1)组在所有三个时间点的骨体积均显著高于未治疗的对照组(2周、4周和8周时分别为249%、227%和266%)。TCP-0.1组的缺损闭合百分比、骨矿物质含量和骨矿物质密度也高于其他组。
与α-TCP颗粒联合使用时,0.1毫克辛伐他汀是刺激大鼠颅骨缺损最大程度骨再生且不引发炎症的最佳剂量,可作为一种有效的骨移植材料应用。